{"id":33,"date":"2024-11-20T17:15:32","date_gmt":"2024-11-20T17:15:32","guid":{"rendered":"https:\/\/www.vimizim.com\/en-us\/?page_id=33"},"modified":"2026-05-05T19:53:03","modified_gmt":"2026-05-05T19:53:03","slug":"side-effects","status":"publish","type":"page","link":"https:\/\/www.vimizim.com\/en-us\/side-effects\/","title":{"rendered":"Side Effects"},"content":{"rendered":"<div id=\"acf-block-674df8455bc98\" class=\"page-header\">         \n            \n        <div class=\"header-image\" style=\"background-image: url(https:\/\/www.vimizim.com\/en-us\/wp-content\/uploads\/sites\/2\/2024\/12\/about_hero.png?v=0.58)\"><\/div>\n     \n    <div class=\"header-content\">\n                    <h1>Side effects of VIMIZIM<sup>\u00ae<\/sup> (elosulfase alfa)<\/h1>\n            <\/div>\n<\/div>\n\n<div id=\"acf-block-67436301ce3e8\" class=\"block split-content equal-bias\" data-muted-autoplay=\"false\">\n\t<div class=\"wrapper\">\n\t\t<div class=\"inner-wrapper\">\n\t\t                                                                <div class=\"content-block first-block\">\n                                                                                                <h2>What are the possible side effects of\u00a0VIMIZIM?<\/h2>\n<ul>\n<li class=\"body\">Serious and severe reactions were associated with VIMIZIM, including hypersensitivity reactions as well as life-threatening allergic reactions (anaphylaxis). In clinical trials, 18.7% of patients treated with VIMIZIM experienced hypersensitivity reactions and 7.7% experienced anaphylaxis<\/li>\n<li class=\"body\">Patients with acute febrile or respiratory illness at the time of VIMIZIM infusion may be at higher risk of life-threatening complications from hypersensitivity reactions<\/li>\n<li>In the clinical trials, anaphylaxis occurred during VIMIZIM infusions and up to 3 hours after the infusion<\/li>\n<\/ul>\n                                                                                    <\/div>\n                    \n                                            <div class=\"content-block second-block\">\n                                                                                                                                                                                                                                                                                    \n                                    \n                                    \n                                    \n                                    <figure>\n                                        <div class=\"image\">\n                                                                                            <img decoding=\"async\" class=\"\" src=\"https:\/\/www.vimizim.com\/en-us\/wp-content\/uploads\/sites\/2\/2026\/04\/Vimizim_DTC_Table_Image_v3-1900x1559.png\" alt=\"imizim DTC Table\" \/>                                                                                    <\/div>\n                                                                            <\/figure>\n                                                                                    <\/div>\n                                                \t\t<\/div>\n\t<\/div>\n<\/div>\n\n<div id=\"acf-block-67436554306e8\" class=\"block wrapped-content bg-band bg-band-primary block-zero-bottom block-remove-bottom-padding\">\n    <div class=\"wrapper\">\n        <div class=\"inner-wrapper\">\n                \n<div id=\"acf-block-6743655430848\" class=\"block-wysiwyg\">\n            <h3>Serious adverse reactions associated with VIMIZIM should be addressed with appropriate medical support<\/h3>\n    <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\n<div id=\"acf-block-674365543157c\" class=\"block split-content equal-bias bg-band bg-band-primary content-align-top block-zero-top block-remove-top-padding\" data-muted-autoplay=\"false\">\n\t<div class=\"wrapper\">\n\t\t<div class=\"inner-wrapper\">\n\t\t                                                                <div class=\"content-block first-block\">\n                                                                                                <ul>\n<li>As a precaution, you should receive medication, such as antihistamines with or without antipyretics (fever reducers), before VIMIZIM infusions to reduce the risk of reactions<\/li>\n<li>Your infusion nurse should check on you while you receive treatment to make sure everything is going well. If you notice any unusual symptoms, tell your nurse right away<\/li>\n<li>Your infusion should be supervised by a healthcare professional knowledgeable in the management of hypersensitivity reactions including anaphylaxis<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.vimizim.com\/en-us\/getting-started-on-vimizim\/\">Learn more about VIMIZIM support from BioMarin &gt;<\/a><\/p>\n                                                                                    <\/div>\n                    \n                                            <div class=\"content-block second-block\">\n                                                                                                <ul>\n<li>If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, the infusion should be stopped and appropriate medical treatment should be initiated immediately, including the use of epinephrine<\/li>\n<li>If a reaction occurs, the infusion should be slowed or stopped, and you may be given additional medication<\/li>\n<li>Your doctor and nurses will work with you to develop a plan to address any possible reactions that could occur during or after your infusion<\/li>\n<\/ul>\n                                                                                    <\/div>\n                                                \t\t<\/div>\n\t<\/div>\n<\/div>\n\n<div id=\"acf-block-674366de9986f\" class=\"block split-content equal-bias\" data-muted-autoplay=\"false\">\n\t<div class=\"wrapper\">\n\t\t<div class=\"inner-wrapper\">\n\t\t                                                                <div class=\"content-block first-block\">\n                                                                                                <h2>What are the possible long-term side effects of\u00a0VIMIZIM?<\/h2>\n<p>No new serious adverse reactions were reported in the long-term extension study.<\/p>\n<ul>\n<li>173 of 176 patients enrolled in the 24-week phase 3 study continued into the 120-week extension study<\/li>\n<li>The most common adverse reactions were infusion-associated and were managed with symptomatic treatment and\/or modification of infusion rate<\/li>\n<li>In the VIMIZIM 2 mg\/kg\/week group (who received 120 weeks of drug), the rate of drug discontinuation due to adverse reactions was 1.8%<\/li>\n<\/ul>\n                                                                                    <\/div>\n                    \n                                            <div class=\"content-block second-block\">\n                                                                                                                                                                                                                                                                                    \n                                    \n                                    \n                                    \n                                    <figure>\n                                        <div class=\"image\">\n                                                                                            <img decoding=\"async\" class=\"\" src=\"https:\/\/www.vimizim.com\/en-us\/wp-content\/uploads\/sites\/2\/2024\/11\/Group-21.png?v=0.58\" alt=\"\" \/>                                                                                    <\/div>\n                                                                            <\/figure>\n                                                                                    <\/div>\n                                                \t\t<\/div>\n\t<\/div>\n<\/div>\n\n<div id=\"acf-block-67436a746691f\" class=\"block wrapped-content\">\n    <div class=\"wrapper\">\n        <div class=\"inner-wrapper\">\n                \n<div id=\"acf-block-67436a7466a9d\" class=\"block-wysiwyg\">\n            <p style=\"text-align: right\"><a href=\"https:\/\/www.vimizim.com\/en-us\/getting-started-on-vimizim\/\">Learn how BioMarin RareConnections\u2122 can help support patients getting started on VIMIZIM &gt;<\/a><\/p>\n    <\/div>\n        <\/div>\n    <\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-33","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Side Effects - BioMarin Vimizim Patient EN-US<\/title>\n<meta name=\"description\" content=\"The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. View important safety information, including risk of anaphylaxis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.vimizim.com\/en-us\/side-effects\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Side effects\" \/>\n<meta property=\"og:description\" content=\"The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. View important safety information, including risk of anaphylaxis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.vimizim.com\/en-us\/side-effects\/\" \/>\n<meta property=\"og:site_name\" content=\"BioMarin Vimizim Patient EN-US\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-05T19:53:03+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/side-effects\\\/\",\"url\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/side-effects\\\/\",\"name\":\"Side Effects - BioMarin Vimizim Patient EN-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/#website\"},\"datePublished\":\"2024-11-20T17:15:32+00:00\",\"dateModified\":\"2026-05-05T19:53:03+00:00\",\"description\":\"The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. View important safety information, including risk of anaphylaxis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/side-effects\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/side-effects\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/side-effects\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Side Effects\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/#website\",\"url\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/\",\"name\":\"BioMarin Vimizim Patient EN-US\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Side Effects - BioMarin Vimizim Patient EN-US","description":"The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. View important safety information, including risk of anaphylaxis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vimizim.com\/en-us\/side-effects\/","og_locale":"en_US","og_type":"article","og_title":"Side effects","og_description":"The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. View important safety information, including risk of anaphylaxis.","og_url":"https:\/\/www.vimizim.com\/en-us\/side-effects\/","og_site_name":"BioMarin Vimizim Patient EN-US","article_modified_time":"2026-05-05T19:53:03+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.vimizim.com\/en-us\/side-effects\/","url":"https:\/\/www.vimizim.com\/en-us\/side-effects\/","name":"Side Effects - BioMarin Vimizim Patient EN-US","isPartOf":{"@id":"https:\/\/www.vimizim.com\/en-us\/#website"},"datePublished":"2024-11-20T17:15:32+00:00","dateModified":"2026-05-05T19:53:03+00:00","description":"The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. View important safety information, including risk of anaphylaxis.","breadcrumb":{"@id":"https:\/\/www.vimizim.com\/en-us\/side-effects\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vimizim.com\/en-us\/side-effects\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.vimizim.com\/en-us\/side-effects\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.vimizim.com\/en-us\/"},{"@type":"ListItem","position":2,"name":"Side Effects"}]},{"@type":"WebSite","@id":"https:\/\/www.vimizim.com\/en-us\/#website","url":"https:\/\/www.vimizim.com\/en-us\/","name":"BioMarin Vimizim Patient EN-US","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vimizim.com\/en-us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/pages\/33","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/comments?post=33"}],"version-history":[{"count":28,"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/pages\/33\/revisions"}],"predecessor-version":[{"id":896,"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/pages\/33\/revisions\/896"}],"wp:attachment":[{"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/media?parent=33"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}